Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs
- PMID: 31416989
- DOI: 10.12809/hkmj195089
Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs
Conflict of interest statement
JCN Chan is the Chief Executive Officer (on pro-bono basis) of Asia Diabetes Foundation, a charitable foundation established under The Chinese University of Hong Kong Foundation for developing the JADE Technology. She has received honoraria and travelling support for consultancy or giving lectures and her affiliated institutions have received research and educational grants from Amgen, Ascencia, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi- Sankyo, Eli-Lilly, GlaxoSmithKline, Medtronic, Merck Serono, Merck Sharp & Dohme, Novo Nordisk, Pfizer, and Sanofi. LL Lim has received honoraria and travelling support for giving lectures and her affiliated institutions have received research and educational grants from AstraZeneca, Boehringer Ingelheim, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Procter & Gamble, Sanofi, and Servier.
Comment on
-
Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus.Hong Kong Med J. 2019 Aug;25(4):312-319. doi: 10.12809/hkmj197802. Hong Kong Med J. 2019. PMID: 31416990 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical